Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial

The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients cou...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Brett, Guttman-Yassky, Emma, Peeva, Elena, Banerjee, Anindita, Zhu, Linda, Zhu, Hua, Cox, Lori Ann, Vincent, Michael S., Sinclair, Rodney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579791/
https://www.ncbi.nlm.nih.gov/pubmed/36277481
http://dx.doi.org/10.1016/j.xjidi.2022.100156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579791/
https://www.ncbi.nlm.nih.gov/pubmed/36277481
http://dx.doi.org/10.1016/j.xjidi.2022.100156

Ejemplares similares